FDA Clearance Tracker · P150004-S040
Axium Neurostimulator System
Last checked: Nov 20, 2026Latest source record: Jan 21, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jan 21, 2021
Approved
Time to decision
234 days
Received Jun 1, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P150004-S040
- Device name
- Axium Neurostimulator System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Jun 1, 2020
- Decided
- Jan 21, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P150004
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS0 protocol.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
- EnSite X EP System510(k)
K261729 · Decided Sep 17, 2026 · 114 days after receipt
Device type: Computer, Diagnostic, Programmable (DQK) · Cardiology
- TactiFlex Duo Ablation Catheter, Sensor Enabled (A-TFDM-D, A-TFDM-F, A-TFDM-J, A-TFDM-DD, A-TFDM-DF, A-TFDM-FF, A-TFDMPMA supplement
P220013-S028 · Decided Sep 4, 2026 · 186 days after receipt · Panel Track
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.